Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISAL 2019 | Bunctional PD-1 x αCD3 x αCD33 CiTE for AML

Marion Subklewe • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies Checkpoint inhibitors

Marion Subklewe, MD, of LMU Hospital Munich, Munich, Germany, discusses the bunctional PD-1 x αCD3 x αCD33 checkpoint inhibitory T cell-engaging (CiTE) antibody for acute myeloid leukemia. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Marion Subklewe

Immunotherapy in AML: translational insights and promising avenues being explored
17:15
Immunotherapy in AML: translational insights and promising avenues being explored
Marion Subklewe • 20 Sep 2025
Immunotherapeutics in AML
Immunotherapeutics in AML
Marion Subklewe • 29 Sep 2022
T-cell engagers and CARs in myeloid malignancies
12:20
T-cell engagers and CARs in myeloid malignancies
Marion Subklewe • 13 Apr 2025
Optimizing bridging therapy before CAR-T in patients with lymphoma
2:56
Optimizing bridging therapy before CAR-T in patients with lymphoma
Marion Subklewe • 1 Apr 2025

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Marion Subklewe • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Marion Subklewe • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Marion Subklewe • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Marion Subklewe • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals